Ipca Laboratories Limited is a consumer-led global pharmaceutical company, operating since 1949. With a presence in over 120 countries on 6 continents, Ipca is known for its high-quality standards and commitment to safety. The company manufactures over 350 formulations and 80 APIs, making it one of the world’s largest suppliers of APIs. Ipca's fully automated manufacturing facilities are approved by renowned drug regulatory authorities such as UK-MHRA, EDQM-Europe, and WHO-Geneva. Key Highlights: - One of the largest suppliers of APIs worldwide with manufacturing leadership in over 12 APIs globally. - Operates 15 APIs & 11 Formulations manufacturing facilities across the globe. - Leader in DMARDs (Disease Modifying Anti-Rheumatic Drugs) for Rheumatoid Arthritis treatment and offers leading brands in Pain, Rheumatology, Antimalarials, and Hair care therapy. - 4 formulations rank amongst the top 300 brands of IPM as per IQVIA. Ipca Laboratories Limited's strong presence in the global pharmaceutical market, wide product range, and adherence to stringent quality standards position it as an attractive investment opportunity for venture capitalists seeking exposure to the healthcare sector.
There is no investment information
No recent news or press coverage available for Ipca Laboratories Limited.
We care about your data, and we'd love to use cookies make your experience better.
